4D Molecular Therapeutics (FDMT) Depreciation and Depletion (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Depreciation and Depletion data on file, last reported at $1.3 million in Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $1.3 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.2 million (up 6.12% YoY), and the FY2025 annual result was $5.2 million, up 8.33% from the prior year.
• Depreciation and Depletion steadied at $1.3 million in Q1 2026 per FDMT's latest filing, from $1.3 million in the prior quarter.
• Over five years, Depreciation and Depletion peaked at $1.3 million in Q4 2023 and troughed at $400000.0 in Q1 2022.
• A 5-year average of $1.1 million and a median of $1.2 million in 2024 frame the typical range for Depreciation and Depletion.
• The sharpest annual moves came in 2022 and 2024: Depreciation and Depletion surged 150.0% in 2022, then slipped 7.69% in 2024.
• A 5-year view of Depreciation and Depletion shows it stood at $1.0 million in 2022, then grew by 30.0% to $1.3 million in 2023, then decreased by 7.69% to $1.2 million in 2024, then advanced by 8.33% to $1.3 million in 2025, then changed by 0.0% to $1.3 million in 2026.
• Business Quant data shows FDMT's Depreciation and Depletion at $1.3 million in Q1 2026, $1.3 million in Q4 2025, and $1.3 million in Q3 2025.